BCL2 and type 2 diabetes mellitus: However, these adverse effects were mitigated following 30 days of SITG administration in diabetic rats, with Bcl-2 levels rising to 634.0 ± 36.06 (p < 0.01) in the T2DM + SITG10 group and 716.0 ± 48.31 (p < 0.01) in the T2DM + SITG30 group.